Form 4 for IBRX ImmunityBio, Inc.
Accepted 2023-09-06 00:00:00 ET · period of report 2023-09-01 · accession 0001326110-23-000114 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-06 | 2023-09-01 | IBRX | LAUER REGAN J | CAO | M - OptEx | $0.00 | +32.9K | 53.9K | +156% | $0 |
| D | 2023-09-06 | 2023-09-01 | IBRX | LAUER REGAN J | CAO | M - OptEx | $0.00 | -32.9K | 32.9K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-01 | M | A | 32,872 | $0.00 | 53,902 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2023-09-01 | M | D | 32,872 | $0.00 | 32,872 | D | — · — to — | 32,872 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F2) Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024. |